OncoMatch/Clinical Trials/NCT06062745
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Is NCT06062745 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including 18F-fluciclovine and PET/CT for advanced prostate cancer.
Treatment: 18F-fluciclovine · PET/CT — This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features. The name of the study interventions are: * 18F-fluciclovine-PET/CT scan * Two research blood collections
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Neuroendocrine Tumor
Biomarker criteria
Required: FOLH1 low expression (whole-body SUVmean ≤ 10 by 68Ga-PSMA-11 PET/CT) (SUVmean ≤ 10)
PSMA-low disease defined by whole-body SUVmean ≤ 10 determined by standard-of-care 68Ga-PSMA-11 PET/CT imaging
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber Cancer Institute · Boston, Massachusetts
- Brigham and Womens Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify